EXECUTIVE SUMMARY
Weight loss and metabolic health is the single fastest-reconfigured consumer health category in modern history. GLP-1 receptor agonists - Ozempic, Wegovy, Mounjaro, Zepbound - have added a pharmaceutical layer to a category that was, as recently as 2022, defined almost entirely by behavioral programs, diet apps, and packaged meal services. The category is now projected to reach $150 billion globally by 2030, with the GLP-1 segment alone crossing $100 billion.
The buying journey has moved in parallel. Consumers no longer start with a primary care physician or a weight-loss-program sales call. They start with ChatGPT, Claude, and Perplexity. "Which GLP-1 is best for me," "Wegovy vs Zepbound," "is Noom worth it in 2026," "what's the best diet app for sustainable weight loss" - these queries route consumers to providers, programs, and products before any clinical or commercial conversation happens.
AI Overviews trigger on health-adjacent queries at approximately 13% - the highest rate of any major consumer category. For weight loss specifically, the rate runs higher still, because the queries are information-seeking rather than transactional. The brands that surface first inside AI answers are the brands that get the consultation, the subscription, and the sale.
Two pharmaceutical companies now own nearly 100% of pharmacology citations in AI answers for this category. Six pharma brands together account for approximately 58% of total citation share. Every legacy weight loss brand in America is recalibrating against that reality - and AI citation share is the scoreboard. 5W built this index to score the new game.
Medical disclaimer. This index is a marketing and communications research document. It does not rank products on clinical effectiveness, safety, or appropriateness, and it does not constitute medical advice. Weight loss decisions are medical decisions that should be made with a licensed clinician.
KEY FINDINGS BAR (8 stat cards)
- STAT 1: $150B - projected global category size by 2030
- STAT 2: ~58% - of total category AI citation share captured by six pharma brands
- STAT 3: 2 - companies (Novo Nordisk and Eli Lilly) own nearly 100% of GLP-1 citations
- STAT 4: ~13% - AI Overview trigger rate on health queries, highest of any consumer category
- STAT 5: 60-70% - share of "best diet app" AI answers citing MyFitnessPal first
- STAT 6: 200M+ - registered MyFitnessPal user base, the informational moat behind its citation lock
- STAT 7: 60+ - consumer prompts tracked across ChatGPT, Claude, Perplexity, and Google AI Overviews to build the index
- STAT 8: 25 - brands ranked, with the remaining ~11% citation share split across ranks 16-25 and unranked brands
THE TOP 15 BY AI CITATION SHARE
Estimated share of citations across 60+ weight-loss-related consumer prompts run through ChatGPT, Claude, Perplexity, and Google AI Overviews, Q1 2026.
- 1. Wegovy - 19.0% citation share - GLP-1 / Pharmaceutical
- 2. Zepbound - 16.0% citation share - GLP-1 / Pharmaceutical
- 3. Ozempic - 13.0% citation share - GLP-1 / Pharmaceutical (T2D-approved, off-label use flagged)
- 4. Mounjaro - 7.0% citation share - GLP-1 / Pharmaceutical (T2D-approved, off-label use flagged)
- 5. Noom - 7.0% citation share - Behavioral Program (hybrid post-Noom Med)
- 6. WeightWatchers - 7.0% citation share - Behavioral Program (Chapter 11 emerged GLP-1-centric)
- 7. MyFitnessPal - 6.0% citation share - Diet / Nutrition App
- 8. Lose It! - 3.0% citation share - Diet / Nutrition App
- 9. Cronometer - 2.0% citation share - Diet / Nutrition App (high-accuracy niche)
- 10. Simple - 2.0% citation share - Diet / Nutrition App (intermittent fasting)
- 11. Saxenda - 2.0% citation share - GLP-1 / Pharmaceutical (declining as weekly options expand)
- 12. Factor - 1.5% citation share - Meal Delivery (HelloFresh portfolio)
- 13. Optavia - 1.5% citation share - Behavioral Program (NYSE: MED)
- 14. Jenny Craig - 1.0% citation share - Behavioral Program (closed 2023, relaunched 2024)
- 15. Nutrisystem - 1.0% citation share - Behavioral Program (Kainos Capital)
Source: 5W analysis of AI-generated responses across ChatGPT, Claude, Perplexity, and Google AI Overviews, Q1 2026. Remaining ~11% split across ranks 16-25 and unranked brands. Telehealth providers excluded from this index and tracked separately.
METHODOLOGY
5W analyzed more than 60 common consumer prompts across five primary sub-categories of the weight loss and metabolic health market. We identified which brands AI models consistently surface, which review aggregators and editorial sources feed those citations, and where the biggest gaps sit between market position and AI visibility.
Sub-Categories Tracked:
- Pharmaceutical GLP-1s: Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza, plus the prescription-adjacent Plenity
- Behavioral weight loss programs: WeightWatchers, Noom, Jenny Craig, Nutrisystem, Optavia, Profile by Sanford, Found
- Diet and nutrition apps: MyFitnessPal, Lose It!, Cronometer, Simple, Yazio, Fastic, Zero, MacroFactor, Carb Manager, Lumen
- Packaged meal services: Factor, Trifecta, Territory, Green Chef, Seattle Sutton
- Supplements & OTC: Hydroxycut, Leanbean, PhenQ, fiber-based weight management products
Query Types Tracked: Real consumer prompts including "best weight loss drug 2026," "Wegovy vs Zepbound," "is Noom worth it," "WeightWatchers vs Noom," "best weight loss app without subscription," "best meal delivery for weight loss," and 50+ additional variations covering comparison, evaluation, and recommendation intent.
Citation Sources Tracked: Medical editorial (WebMD, Healthline, GoodRx, Drugs.com, Everyday Health), clinical authorities (NIH, CDC, FDA, Mayo Clinic, Cleveland Clinic, Harvard Health Publishing), review aggregators (Forbes Health, U.S. News Health, Wirecutter), patient communities (Reddit, Facebook groups), news coverage (CNBC, Bloomberg, Reuters, STAT News, FiercePharma), and vendor-owned content hubs.
Important framing. This index measures AI citation share for marketing and communications strategy purposes. It does not rank products on clinical effectiveness, safety, or appropriateness, and it does not constitute medical advice. Weight loss decisions are medical decisions that should be made with a licensed clinician. Telehealth providers are excluded from this edition of the index and will be covered separately. If you or someone you know is struggling with disordered eating, the National Alliance for Eating Disorders helpline is at 1-866-662-1235.
THE WINNERS
The Pharma Duopoly: Novo Nordisk and Eli Lilly. Novo and Lilly together own approximately 95%-plus of GLP-1 prescription volume and a similar share of AI citations for pharmacology queries. The reason is structural. They are the only FDA-approved options for chronic weight management (Wegovy, Zepbound) and the only sources of authoritative clinical trial data - STEP, SURMOUNT, and SELECT trials - that AI models cite as evidence. Zepbound's recent trajectory illustrates the citation compounding dynamic. The SURMOUNT-5 head-to-head trial against Wegovy, published in 2025, demonstrated superior weight loss for tirzepatide. That data point is now cited in nearly every "Wegovy vs Zepbound" AI answer, and the citation itself has driven prescription volume. Every clinical trial publication is, in effect, an AI citation event.
Noom and WeightWatchers: Two Different Pivot Stories. Noom and WeightWatchers have both pivoted into the GLP-1 era - with dramatically different financial outcomes but similar citation outcomes. Noom's pivot, with Noom Med launched late 2022, has been successful in AI citation terms. The company positioned itself as "behavioral change plus medication access" rather than abandoning its behavioral roots, and AI answers now consistently cite Noom as the category's hybrid default. WeightWatchers' pivot has been financially brutal - the company filed Chapter 11 in 2025 and emerged with a GLP-1-centric strategy - but its AI citation share remains strong because of 60-plus years of accumulated brand equity and content. WW is still the default "traditional weight loss program" AI citation, even when its current business looks nothing like its historical one.
MyFitnessPal: The Category-Defining App. MyFitnessPal is cited in an estimated 60-70% of "best diet app" AI answers. The 15-year head start on food-database construction, 200 million-plus user base, and deep content library create a compounding moat that newer apps (Simple, MacroFactor, Carb Manager) cannot displace through product quality alone. When AI models train on the full archive of consumer reviews, app-store metadata, and editorial comparisons, MyFitnessPal sits at the center of that weight class. Owned by Francisco Partners.
The Specialty Specialists. Cronometer (high-accuracy macros), Simple (intermittent fasting), Carb Manager (keto), and MacroFactor (adaptive coaching) win narrow long-tail queries by owning specific sub-categories rather than competing for generic "best diet app" citations. This is the only reliable path to AI citation share for new apps: own a sub-category before competing for the category.
THE LOSERS
The Legacy Behavioral Brands. Jenny Craig, Nutrisystem, Optavia, and Medifast - the 2000s-era behavioral and meal-replacement brands - are being cited at a fraction of their historical share. AI answers increasingly frame them as "before GLP-1s, people tried..." rather than as current first-choice options. Jenny Craig's 2023 closure and 2024 relaunch has further weakened citation consistency, with AI answers frequently returning outdated information about the brand's status - a reputation management problem in itself.
The Meal Delivery Squeeze. Factor, Green Chef, Trifecta, Territory, and Seattle Sutton remain relevant for specific long-tail queries but have lost generic "how to lose weight" citation share to the GLP-1 plus behavioral combination. Meal delivery AI citations are increasingly framed as adjuncts to medication-based weight loss rather than as standalone solutions. The category is not dying. It is being recategorized.
The Supplement Category Collapse. Hydroxycut, Leanbean, PhenQ, Garcinia cambogia products, apple cider vinegar capsules - the OTC supplement category for weight loss has lost nearly all generic AI citation share to GLP-1s and Plenity (the only FDA-cleared OTC-adjacent option). AI models increasingly flag supplement claims with evidence caveats, further reducing citation surface. A category that generated billions in revenue a decade ago is now nearly invisible in the AI-mediated buying journey.
SIX STRUCTURAL TRUTHS
- 1. AI citations update faster here than in any other consumer health category. FDA shortage list changes, trial publications, and regulatory enforcement generate citation-shifting news cycles roughly every 2-3 weeks. Brands that miss a news cycle lose citation share. The next news cycle compounds on the last.
- 2. Clinical trial publication is the highest-leverage citation event in the category. SURMOUNT-5. SELECT. STEP. These peer-reviewed publications are cited in AI answers for years and drive measurable changes in which drug AI recommends. Trial publication is now both a financial event and a marketing event.
- 3. Behavioral content wins "before you start" queries. Queries like "how to lose weight without medication," "is GLP-1 right for me," and "what to try before Ozempic" default to Noom, WeightWatchers, and MyFitnessPal - not pharma. Behavioral brands that maintained content velocity through the GLP-1 era have held this citation surface.
- 4. App category moats are built on databases, not features. MyFitnessPal's food database is a 15-year advantage. Simple's fasting protocol library. Carb Manager's keto recipe archive. The citation moats are informational, not functional - which means new entrants cannot catch up through UX improvement alone.
- 5. Sub-category dominance beats category competition. Generalist positioning loses to specialist positioning in AI citations. Cronometer owns "accuracy." Simple owns "fasting." Carb Manager owns "keto." Factor owns "weight-loss meals." Brands trying to be the "best overall" lose to brands that own a specific sub-query.
- 6. Regulatory events are a category risk surface. FDA enforcement decisions, Medicare coverage rulings, and state pharmacy board actions can reshape the citation landscape within weeks. Brands without active regulatory-communications infrastructure are exposed to sudden citation erosion they cannot respond to in time.
SIX 2026 DYNAMICS RESHAPING WEIGHT LOSS AI CITATIONS
- 01. The Wegovy-vs-Zepbound narrative has solidified in AI. SURMOUNT-5's 2025 publication created a sticky "Zepbound beats Wegovy" narrative that now appears in the majority of comparison AI answers. Novo Nordisk's 2026 response - new CagriSema data and oral semaglutide positioning - is beginning to shift citations back toward parity.
- 02. The Medicare coverage decision is a pending citation event. CMS's evaluation of Medicare Part D coverage for obesity drugs would, if approved, generate a category-wide citation shift. Brands publishing substantive content on the coverage question are positioned to own the post-decision citation surface.
- 03. Oral GLP-1 approvals are a 2026-2027 reshuffling event. Novo Nordisk's oral semaglutide and Eli Lilly's orforglipron (Phase 3) could eliminate the injection barrier. Oral approval for obesity would shift AI citations meaningfully as consumer hesitation around injections disappears.
- 04. The GLP-1 maintenance question is its own citation surface. "What happens when you stop taking Wegovy" and "can you stay on GLP-1s forever" are among the fastest-growing queries in the category. Evidence-based content is thin. Brands publishing authoritative maintenance content in 2026 will own a citation surface that has not yet been locked.
- 05. Behavioral-plus-medication hybrid positioning is the winning model. Noom's pivot proved the most durable AI citation position combines behavioral support with medication access. Every behavioral brand that maintains pharma-adjacent content will hold citation share. Every pharma brand that adds behavioral-support narrative will do the same.
- 06. Eating disorder screening language is becoming an AI signal. AI models are increasingly trained to surface ED-screening content when weight-loss queries contain disordered-eating signals. Brands whose content includes responsible framing gain citation share - and avoid reputation risk from being cited alongside concerning queries.
FROM RONN TOROSSIAN, FOUNDER OF 5W
"Two pharmaceutical companies now own nearly 100% of GLP-1 citations in AI answers. Six pharma brands take roughly 58% of the entire category. That is not a market share story. It is a marketing infrastructure story. Novo Nordisk and Eli Lilly built the citation moat the same way every other category leader will eventually have to build it: peer-reviewed clinical data, named-author editorial coverage, regulatory events treated as content events, and a content cadence faster than the news cycle. The behavioral brands and the apps and the meal services that figure out how to play that game in the next two quarters will hold their citation surface. The ones that do not will get categorized as 'before GLP-1s, people tried...' inside an AI answer that someone else's brand is leading. AI citation share is the scoreboard. Most brands in this category are not yet playing."
THE WEIGHT LOSS MARKETER PLAYBOOK
- 1. Audit AI citation share monthly. This category moves fast enough that anything less frequent misses material citation shifts. Monthly is the minimum defensible cadence.
- 2. Publish clinical data, not marketing claims. AI answers reward peer-reviewed evidence and down-rank marketing language. Every brand in this category should have a clinical content pipeline, not a brand-voice blog.
- 3. Treat FDA events as content events. Shortage list changes, approval decisions, enforcement actions, Medicare coverage updates - each is a content opportunity that most brands under-exploit.
- 4. Publish physician bylines. Named, credentialed obesity-medicine specialists carry AI citation weight that ghost-written corporate content does not.
- 5. Own a sub-category if you cannot compete broadly. Specialist positioning beats generalist positioning in AI citations. Pick a lane and dominate it.
- 6. Address the maintenance question aggressively. The GLP-1 off-ramping and weight-maintenance content gap is the single biggest greenfield citation opportunity in the category.
- 7. Stay off "cheapest way to get Ozempic" framing. AI models flag this as encouraging off-label use or regulatory gray-area purchasing. Compliant positioning beats price positioning for AI citation.
- 8. Include eating disorder screening language. The right framing around when weight loss is and is not appropriate protects AI citation share and minimizes reputational exposure.
- 9. Build out your clinical trial content pipeline. Every trial read-out is a citation event for a year afterward. Pharma and pharma-adjacent brands should be publishing trial commentary from credentialed clinicians within 24 hours of every major publication.
- 10. Re-audit after every FDA news cycle. Shortage changes, enforcement actions, and coverage decisions reshape citations within weeks. The monthly audit is the floor; event-driven re-audits are the ceiling.
THE BIGGER PICTURE
Weight loss is the most structurally disrupted consumer health category of the past decade. Pharmaceutical innovation has rewritten buyer behavior. AI has disintermediated the traditional discovery pathway. The brands that surface inside ChatGPT and Claude answers are now doing the work that doctors, friends, and Google search results used to do.
The brands that dominate AI citations over the next 24 months will not just capture market share - they will shape how millions of Americans make decisions about medications, programs, and products that materially affect their health. This is a category where AI visibility translates directly to revenue, and where responsible framing matters as much as aggressive distribution.
The pharma duopoly is unlikely to be dislodged in this decade. The behavioral-program pivot has a proven winner (Noom) and a proven survivor (WeightWatchers). The app category's moats are informational. The meal-delivery, supplement, and legacy-program categories are being recategorized in real time inside AI answers that very few of those brands have yet optimized for.
AI citation share is the scoreboard. Most brands in this category are not yet playing.
